C52H48N6O6
Neat
852.99
Trityl candesartan cilexetil; 170791-09-0; UNII-006A6A2YSO; 006A6A2YSO; Candesartan cilexetil impurity H [EP]; Candesartan cilexetil specified impurity H [EP]; EC 605-586-7; (1RS)-1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 2-ethoxy-1-((2'-(1-(triphenylmethyl)-1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-benzimidazole-7-carboxylate; 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1-(triphenylmethyl)-1H-tetrazol-5-yl)(1, 1'-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester; 2-Ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-1, 1'-biphenyl-4-yl)methyl)-7-benzimidazolecarboxylic acid 1-(cyclohexyloxycarbonyloxy)ethyl ester; CANDESARTAN CILEXETIL IMPURITY H [EP IMPURITY]; 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1, 1'-biphenyl]-4-yl]methyl]- and 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester; CANDESARTAN CILEXETIL IMPURITY H (EP IMPURITY); (+-) 1-(CYCLOHEXYLOXYCARBONYLOXY)ETHYL-2-ETHOXY-1-((2'-(TRIPHENYLMETHYLTETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)1H-BENZIMIDAZOLE-7-CARBOXYLATE; (+-) 1-(CYCLOHEXYLOXYCARBONYLOXY)ETHYL-2-ETHOXY-1-[[2'-(TRIPHENYLMETHYLTETRAZOL-5-YL)BIPHENYL-4-YL]METHYL]1H-BENZIMIDAZOLE-7-CARBOXYLATE; RefChem:192215; Candesartan cilexetil impurity H; Candesartan cilexetil specified impurity H; (+-)-TRITYL CANDESARTAN CILEXETIL; (+-)-1-(Ciclohexiloxicarboniloxi)etil-2-etoxi-1-((2'-(trifenilmetiltetrazol-5-il)bifenil)-4-il)metil)-1H-bencimidazol-7-carboxilato
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(1-trityltetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
InChI=1S/C52H48N6O6/c1-3-61-50-53-46-30-18-29-45(49(59)62-36(2)63-51(60)64-42-25-14-7-15-26-42)47(46)57(50)35-37-31-33-38(34-32-37)43-27-16-17-28-44(43)48-54-55-56-58(48)52(39-19-8-4-9-20-39,40-21-10-5-11-22-40)41-23-12-6-13-24-41/h4-6,8-13,16-24,27-34,36,42H,3,7,14-15,25-26,35H2,1-2H3